Clinical trial · Interventional
Cell-free Tumor DNA in Head and Neck Cancer Patients
Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer
NCT03942380CI-TRIAL-00053978unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting recurrence in patients already diagnosed and treated for head and neck squamous cell carcinoma.
Conditions
Conditions (27)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Head and Neck Neoplasms | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hypopharynx Cancer | Malignant Hypopharyngeal Neoplasm | ALIAS | 0.90 |
| Hypopharynx Carcinoma | — | UNRESOLVED | — |
| Hypopharynx Neoplasm | — | UNRESOLVED | — |
| Larynx Cancer | Malignant Laryngeal Neoplasm | CURATED_BROADER | 0.80 |
| Larynx Carcinoma | Laryngeal Carcinoma | ALIAS | 0.90 |
| Larynx Neoplasm | Laryngeal Neoplasm | ALIAS |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liquid biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Cell-free tumor DNA
- description
- The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
- interventionNames
- Diagnostic Test: Liquid biopsy
- type
- OTHER
- label
- Identifying recurrence
- description
- The aim is to identify recurrence through serial monitoring patients with blood samples.
- interventionNames
- Diagnostic Test: Liquid biopsy
Primary outcomes (2)
- measure
- Percentage of head and neck cancer detected with a blood sample
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years old or older * Suspicion of head and neck cancer Exclusion Criteria: * Diagnosed with cancer within the last 3 years ( apart from basal cell carcinoma) * Diagnosed with an inflammatory or haematological disease after the age of 18 * Received chemotherapy or immunosuppressive treatment within the last 3 years * Underwent a FNA ( fine-needle aspiration biopsy) or a biopsy from the head and neck region within 1 week.
References
Publications (0)
Data not yet available
No reference posted for this study.